Addressing an unmet medical need in GERD
Highlights from the 2024 Annual Report: Market overview. Significant proportion of severe eGERD patients treated by Gastroenterologists remain unhealed with PPI treatment.
Read more
In the spotlight
Check out the latest updates from Cinclus Pharma
We develop the future GERD treatment which has roots in AstraZeneca
Highlights from the 2024 Annual Report: Interview with the founders. Cinclus Pharma, founded by a team of experts with deep roots in the pharmaceutical industry, is on a mission to bring an effective GERD treatment, linaprazan glurate, to the market. Building on groundbreaking work done at AstraZeneca.
Read more
A Doctor’s perspective on linaprazan glurate’s unique potential
Highlights from the 2024 Annual Report: Interview with Dr. Prateek Sharma. Dr. Prateek Sharma, Medical Advisor and expert in gastrointestinal diseases and cancer, shares his insights on its safety and potential usage areas.
Read more